CERA, a long acting erythropoiesis stimulating agent in treating renal anaemia in patients with diabetic chronic kidney disease, has been shown to ameliorate increased albuminuria by preventing diabetes-induced podocyte damage in the db/db mouse which was apart from hematopoietic effects and without ...